Skip to main content
Edwards Lifesciences Logo

TRIFORMIS RESILIA tricuspid valve

Triformis banner

The first and only surgical valve designed specifically for the tricuspid position

Triformis overview product
  • Unique sewing ring shape and profile tailored to native tricuspid anatomy
  • Features designed to ease orientation and implantation, and avoid suture looping
  • RESILIA tissue preservation technology, designed to enhance durability*1
  • Built on the trusted PERIMOUNT valve platform

*Clinical data on valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up of up to 10 years in process.

Pre-clinical study performance of the TRIFORMIS RESILIA valve in the tricuspid position demonstrated: 

  • Good leaflet mobility
  • Good hemodynamic performance
  • No significant conduction abnormalities
  • Optimal seating

The TRIFORMIS RESILIA tricuspid valve is a timely innovation

Historically, surgery for isolated tricuspid regurgitation is rarely performed because of perceptions of high mortality.



A new analysis of STS outcomes shows that the risk is lower than previously observed2, providing a new benchmark for current and future isolated tricuspid valve interventions.

5.6%

overall predicted risk of operative mortality

Tricuspid-specific design

Tricuspid-specific design

The sewing ring has a flat profile that mimics the tricuspid annulus and is specifically designed for optimal seating. 

Learn more about the Tricuspid-specific design
Designed for ease of use

Designed for ease of use

The TRIFORMIS RESILIA valve is designed to ease positioning and implantation.

Learn more about the unique design features
Clinical data

Clinical data

See how clinical evidence supports RESILIA tissue valves’ performance.

Learn more about RESILIA tissue clinical evidence

References

  1. Beaver T, Bavaria J, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg.  2023;x:1-11. doi: 10.1016/j.jtcvs.2023.09.047  
  2. Thourani VH, Bonnell L, Wyler von Ballmoos MC, et al. Outcomes of isolated tricuspid valve surgery: a Society of Thoracic Surgeons analysis and risk model. Ann Thorac Surg. 2024;118:873-881. doi: 10.1016/j.athoracsur.2024.04.014
Important Safety Information

Important Safety Information

TRIFORMIS RESILIA Tricuspid Valve

Indications: For use in replacement of native or prosthetic tricuspid heart valves.

Contraindications: The TRIFORMIS RESILIA tricuspid valve is contraindicated in patients who have untreatable hypersensitivity to nitinol alloys (nickel and titanium).

Complications and Side Effects: Thromboembolism, valve thrombosis, hemorrhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstructural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, ventricular perforation by stent posts, any of which could lead to reoperation, explantation, permanent disability, and death.

CAUTION: US law restricts this device to sale by or on the order of a physician. See Instructions for Use for full prescribing information.